A recent study has highlighted the potential impact of gut bacteria on predicting heart risks in older patients undergoing breast cancer treatment. The research indicates that certain gut bacteria may be associated with a higher likelihood of heart damage in these patients, emphasizing the importance of maintaining a healthy gut microbiome.
Patients with breast cancer, particularly older individuals, may benefit from a pre-existing healthy gut microbiome before starting chemotherapy to potentially shield themselves from cardiotoxicity, a common side effect of cancer treatment. Conversely, specific gut bacteria, such as Bacteroides, were found to be more prevalent in patients exhibiting heart health biomarkers linked to an increased risk of heart damage during cancer therapy. These biomarkers include left ventricular global longitudinal strain, N-terminal pro b-type natriuretic peptide, and troponin I, which mirror those seen in individuals with heart failure.
Dr. Athos Antoniades, Head of Research and Development at Stremble Ventures LTD, underlined the necessity of exploring new strategies to safeguard cancer survivors from the long-term consequences of chemotherapy. The study’s findings suggest a significant association between certain gut bacteria and cardiac biomarkers, indicating a potential risk of heart damage in patients undergoing chemotherapy.
The study involved 98 older women with breast cancer across three clinical centers in Europe who underwent heart scans and biomarker assessments to evaluate heart function and potential risks of heart damage during treatment. Genetic sequencing was employed to analyze the composition of gut bacteria before the initiation of cancer therapy. This research is part of the larger CARDIOCARE project, funded by the EU, which aims to further validate these findings in a larger cohort of 600 women and potentially explore personalized probiotics as a means to mitigate heart-related side effects of chemotherapy.
Dr. Vincent Ma, a faculty member at the University of Wisconsin, School of Medicine and Public Health, discussed how the gut microbiome could influence treatment outcomes in melanoma patients, referencing the DIET trial’s findings on the benefits of a high-fiber diet in enhancing treatment response and reducing side effects during immunotherapy. Bacteroidaceae, a common family of gut bacteria, can have both beneficial and harmful effects on health depending on their balance, potentially contributing to inflammation and infections when imbalanced.
As advancements in breast cancer treatments lead to improved survival rates, the incidence of heart damage as a side effect of cancer therapies, such as chemotherapy, becomes more significant. Understanding the role of gut bacteria in predicting and potentially mitigating heart risks during cancer treatment could open new avenues for personalized interventions to enhance patient outcomes and quality of life.
Key Takeaways:
– Maintaining a healthy gut microbiome before chemotherapy could help protect breast cancer patients from heart damage during treatment.
– Specific gut bacteria, like Bacteroides, were associated with heart health biomarkers indicating an elevated risk of heart damage in cancer patients.
– The study’s findings suggest the potential use of personalized probiotics to reduce heart-related side effects of chemotherapy.
– Understanding the influence of gut bacteria on heart risks in breast cancer treatment may lead to tailored interventions for improved patient care and outcomes.
Tags: microbiome, probiotics, immunotherapy
Read more on curetoday.com